摘要
目的:评价苓桂术甘汤加减方联合西药治疗肺源性心脏病的疗效及安全性。方法:利用计算机检索中国知网数据库、维普数据库、万方数据库、中国生物医学文献数据库、Cochrane图书馆数据、PubMed、Embase,查找关于苓桂术甘汤加减方治疗肺源性心脏病的临床随机对照试验(RCT),检索时限均从建库至2022年5月。采用RevMan 5.4软件进行Meta分析。结果:共纳入15项RCT,涉及1 405例患者,其中干预组703例,对照组702例。Meta分析结果提示,干预组有效率[RR=1.20,95%CI(1.14,1.28),P<0.000 01]、动脉血氧分压(PaO_(2))[MD=9.32,95%CI(3.90,14.73),P=0.000 7]、右心室射血分数(RVEF)[MD=4.33,95%CI(3.48,5.18),P<0.000 01]、左心室射血分数(LVEF)[MD=9.23,95%CI(6.88,11.58),P<0.000 01]、第一秒用力呼气容积(FEV1)[MD=0.50,95%CI(0.47,0.53),P<0.000 01]和第一秒用力呼气容积/用力肺活量(FEV1/FVC)[MD=7.54,95%CI(5.23,9.85),P<0.000 01]均高于对照组,动脉血二氧化碳分压(PaCO_(2))[MD=-7.98,95%CI(-10.44,-5.52),P<0.000 01]、肺动脉压(PAP)[MD=-5.09,95%CI(-7.17,-3.01),P<0.000 01]、N-末端B型利钠肽原(NT-pro BNP)[MD=-319.81,95%CI(-621.94,-17.67),P=0.04]均低于对照组。结论:苓桂术甘汤加减方联合西药治疗肺源性心脏病具有较好的临床疗效,未见明显用药不良反应。
Objective:To evaluate the efficacy and safety of Linggui Zhugan Decoction(苓桂术甘汤)combined with western medicine in the treatment of pulmonary heart disease.Methods:CNKI,VIP,Wanfang,China Biomedical Literature Database,Cochrane Library data,PubMed and Embase were used to search for clinical randomized controlled trials(RCT)on Linggui Zhugan Decoction in the treatment of pulmonary heart disease from the establishment of the database to May 2022.RevMan 5.4 software was used for Meta-analysis.Results:A total of 15 RCT were included,involving 1405 patients,including 703 cases in the intervention group and 702 cases in the control group.According to the results of meta-analysis,the intervention'group showed higher effective rate[RR=1.20,95%CI(1.14,1.28),P<0.00001],arterial partial pressure of oxygen(PaO_(2))[MD=9.32,95%CI(3.90,14.73)],P=0.0007],right ventricular ejection fraction(RVEF)[MD=4.33,95%CI(3.48,5.18),P<0.00001],left ventricular ejection fraction(LVEF)[MD=9.23,95%CI(6.88,11.58)],P<0.00001],FEV1[MD=0.50,95%CI(0.47,0.53),P<0.00001]and FEV1/FVC[MD=7.54,95%CI(5.23,9.85)],P<0.00001]than control group,while lower arterial partial pressure of carbon dioxide(PaCO_(2))[MD=-7.98,95%CI(-10.44,-5.52),P<0.00001],pulmonary artery pressure(PAP)[MD=-5.09,95%CI(-7.17,-3.01)],P<0.00001],N-terminal pro-B-type natriuretic peptide(NT-pro BNP)[MD=-319.81,95%CI(-621.94,-17.67),P=0.04]than control group.Conclusion:Linggui Zhugan Decoction combined with western medicine in the treatment of pulmonary heart disease has a good clinical effect and no obvious adverse drug reactions.
作者
史平平
张丽娜
王英杰
郭琳娜
杜双芹
范子盼
SHI Pingping;ZHANG Li'na;WANG Yingjie;GUO Linna;DU Shuangqin;FAN Zipan(Langfang People's Hospital,Langfang Hebei 065000,China;Bazhou Traditional Chinese Medicine Hospital,Bazhou Hebei 065700,China;Hebei Provincial Hospital of Traditional Chinese Medicine,Shijiazhuang Hebei 050013,China)
出处
《中医药导报》
2023年第4期164-170,共7页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
廊坊市科学技术研究与发展计划项目(2020013079)。
